Obesity science & practice

Healthcare Professionals’ Views on Injectable GLP-1 Medicines for Treating Obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Healthcare professionals expressed interest in prescribing injectable GLP-1 drugs for weight management.

  • Injectable GLP-1 drugs like semaglutide and tirzepatide may support weight loss in individuals with obesity.
  • Current UK guidelines recommend these drugs be prescribed in specialized weight management services.
  • Healthcare professionals in a non-prescribing weight management service showed positive views on future prescriptions of these drugs.
  • The study highlights a potential shift in practice within specialist services regarding these medications.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Oct '25
Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes
top 20% journal
cited by 7 papers
journal article
Apr '25
Real-world use, benefits, and side effects of new weight-loss treatments based on GLP-1 receptor activators
top 5% journal
cited by 98 papers
journal article
Jun '25
Summary of studies comparing how well GLP-1 receptor agonists work for weight loss
top 10% journal
cited by 5 papers
systematic review
Jun '26
Patient Experiences Using GLP-1 Receptor Agonist Medications
top 2% journal
journal article
Mar '25
How Using Digital Tools Relates to Weight Loss in People with Obesity Taking GLP-1 or Combined GLP-1/GIP Treatments
top 5% journal
cited by 14 papers
journal article
Nov '22
Folic acid supplements and malaria risk and severity in people using antifolate malaria drugs in affected areas
cited by 30 papers
systematic review
May '25
Remote Specialist Weight Management Program Supported by GLP-1RA for Adults with Obesity: Review of Service Results
top 30% journal
cited by 6 papers
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief